Bain Capital and Cinven to sell most of their stake in STADA to CapVest

On September 1, 2025, Bain Capital and Cinven, two renowned international private equity firms, announced a groundbreaking agreement to sell the majority stake in STADA Arzneimittel AG to CapVest Partners LLP. This decision marks the culmination of their journey since acquiring STADA in 2017 and steering it towards becoming a leading global healthcare powerhouse with a strategic focus on Consumer Healthcare, Generics, and Specialty Pharmaceuticals. The transformation not only saw STADA evolve from a traditional German generics business but also achieve remarkable milestones such as generating revenues exceeding €4 billion, with a staggering compound annual net sales growth rate of 9%, and more than doubling EBITDA since its privatization.

Throughout their ownership, Cinven and Bain Capital played pivotal roles in supporting STADA through more than 25 targeted acquisitions, bolstering its market presence across Europe and internationally. Noteworthy acquisitions included renowned brands such as Johnson & Johnson’s Nizoral brand, Walmark, a portfolio of GlaxoSmithKline’s consumer healthcare brands, and a selection of Sanofi’s European consumer healthcare brands. These strategic acquisitions, coupled with substantial investments and expertise from both firms, have firmly established STADA as a prominent force in the European pharmaceutical landscape today.

The transitioning of STADA’s majority stake to CapVest signifies a promising future for the company, with CapVest’s extensive sector knowledge and proven track record in healthcare investments promising to usher STADA into its next phase of growth. CapVest’s commitment to responsible ownership, operational excellence, and long-term value creation closely aligns with the principles that have driven STADA’s successful evolution thus far.

Furthermore, Bain Capital and Cinven’s decision to maintain a minority stake in STADA following the transaction speaks volumes about their confidence in the company’s future prospects and the proficiency of its management team. This continued investment underscores their unwavering belief in STADA’s trajectory for growth and cements their ongoing commitment to the company’s success in the coming years.